Bank Of Montreal Ironwood Pharmaceuticals Inc Transaction History

Bank Of Montreal

$197 Billion
Q2 2024

A detailed history of Bank Of Montreal transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Bank Of Montreal holds 94,564 shares of IRWD stock, worth $476,602. This represents 0.0% of its overall portfolio holdings.

Number of Shares

94,564

Previous 14,247 563.75%

Holding current value

$476,602

Previous $124,000 396.77%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.58 - $8.61 $448,168 - $691,529	80,317 Added 563.75%	94,564 $616,000
Q1 2024 May 13, 2024	BUY	$8.32 - $15.45 $5,524 - $10,258	664 Added 4.89%	14,247 $124,000
Q4 2023 Feb 08, 2024	BUY	$8.79 - $11.51 $24,058 - $31,502	2,737 Added 25.24%	13,583 $155,000
Q3 2023 Nov 01, 2023	SELL	$8.25 - $11.35 $45,391 - $62,447	-5,502 Reduced 33.66%	10,846 $104,000
Q2 2023 Aug 02, 2023	BUY	$10.1 - $11.6 $28,421 - $32,642	2,814 Added 20.79%	16,348 $173,000
Q1 2023 Jun 13, 2024	BUY	$10.37 - $12.56 $37,446 - $45,354	3,611 Added 25.35%	17,858 $187,000
Q4 2022 Feb 01, 2023	SELL	$9.9 - $12.43 $1,059 - $1,330	-107 Reduced 0.78%	13,534 $167,000
Q3 2022 Nov 10, 2022	SELL	$10.14 - $12.38 $21,010 - $25,651	-2,072 Reduced 13.19%	13,641 $143,000
Q2 2022 Aug 11, 2022	BUY	$11.05 - $12.72 $156,755 - $180,445	14,186 Added 929.01%	15,713 $193,000
Q1 2022 May 12, 2022	BUY	$10.61 - $12.88 $16,201 - $19,667	1,527 New	1,527 $19,000
Q4 2021 Feb 11, 2022	SELL	$10.86 - $13.95 $16,637 - $21,371	-1,532 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$10.16 - $13.11 $15,565 - $20,084	1,532 New	1,532 $20,000

Others Institutions Holding IRWD

# of Institutions

245

Shares Held

170M

Call Options Held

11.2M

Put Options Held

28.5K

View Full List

About IRONWOOD PHARMACEUTICALS INC

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $772M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

More about IRWD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account